Foundations Investment Advisors LLC Acquires Shares of 3,311 Boston Scientific Co. (NYSE:BSX)

Foundations Investment Advisors LLC bought a new position in shares of Boston Scientific Co. (NYSE:BSX) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 3,311 shares of the medical equipment provider’s stock, valued at approximately $296,000.

Other institutional investors also recently made changes to their positions in the company. Pacer Advisors Inc. increased its position in Boston Scientific by 21.8% during the 4th quarter. Pacer Advisors Inc. now owns 138,057 shares of the medical equipment provider’s stock worth $12,331,000 after buying an additional 24,754 shares during the period. Cornerstone Wealth Group LLC increased its position in Boston Scientific by 8.0% during the fourth quarter. Cornerstone Wealth Group LLC now owns 2,762 shares of the medical equipment provider’s stock worth $247,000 after acquiring an additional 205 shares during the period. KBC Group NV raised its stake in Boston Scientific by 1.8% in the 4th quarter. KBC Group NV now owns 2,380,521 shares of the medical equipment provider’s stock worth $212,627,000 after purchasing an additional 41,720 shares in the last quarter. Union Bancaire Privee UBP SA bought a new stake in Boston Scientific in the 4th quarter valued at about $33,074,000. Finally, Blue Trust Inc. grew its position in shares of Boston Scientific by 43.7% during the 4th quarter. Blue Trust Inc. now owns 15,077 shares of the medical equipment provider’s stock worth $1,263,000 after purchasing an additional 4,585 shares in the last quarter. Institutional investors own 89.07% of the company’s stock.

Insider Transactions at Boston Scientific

In other Boston Scientific news, EVP Arthur C. Butcher sold 14,010 shares of the business’s stock in a transaction dated Monday, November 25th. The shares were sold at an average price of $89.27, for a total value of $1,250,672.70. Following the transaction, the executive vice president now directly owns 978 shares in the company, valued at $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP John Bradley Sorenson sold 4,119 shares of the stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $90.02, for a total value of $370,792.38. Following the transaction, the executive vice president now directly owns 35,319 shares of the company’s stock, valued at approximately $3,179,416.38. This trade represents a 10.44 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 29,989 shares of company stock worth $2,702,261 in the last quarter. 0.50% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

BSX has been the subject of several recent research reports. Morgan Stanley boosted their price target on Boston Scientific from $92.00 to $100.00 and gave the company an “overweight” rating in a research note on Thursday, October 24th. BTIG Research boosted their price target on Boston Scientific from $84.00 to $93.00 and gave the company a “buy” rating in a research note on Monday, October 14th. Needham & Company LLC reiterated a “hold” rating on shares of Boston Scientific in a research report on Wednesday, November 27th. Mizuho boosted their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the stock an “outperform” rating in a research note on Thursday, October 24th. Finally, JPMorgan Chase & Co. raised their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Two research analysts have rated the stock with a hold rating, twenty-one have issued a buy rating and one has given a strong buy rating to the stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average target price of $98.35.

Boston Scientific Stock Performance

Shares of BSX opened at $102.40 on Friday. The company has a debt-to-equity ratio of 0.44, a quick ratio of 1.02 and a current ratio of 1.48. The stock has a 50 day moving average price of $93.22 and a two-hundred day moving average price of $86.04. Boston Scientific Co. has a 52 week low of $62.63 and a 52 week high of $104.25. The firm has a market capitalization of $150.92 billion, a P/E ratio of 84.63, a P/E/G ratio of 2.69 and a beta of 0.80.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.